Magenta Therapeutics Unveils Positive MGTA-117 Clinical Data at the American Society of Hematology (ASH) Annual Meeting

(24/7 MARKET NEWS) – Magenta Therapeutics (Nasdaq: MGTA) announced, after yesterday’s market close, that it unveiled updated clinical data from the ongoing MGTA-117 Phase 1/2 dose-escalation clinical trial made in an oral presentation today at the American Society of Hematology 2022 Annual (ASH) Meeting in New Orleans and provided across the portfolio program updates.

Magenta Therapeutics is trading higher in this morning’s premarket, at $1.39, 24 cents higher (+20.87%), on 7 million shares traded.

Its 52-week range is $0.9231 to $5.49. Its next inflection points are $1.82, $1.90 and $2.24.

24/7 MARKET NEWS, INC Disclaimer

24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.

Please go to or for further information.


Signup today for free and be the first to get notified of breaking news.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.


Sign up for Breaking Alerts, our newsletter putting timely and updated stock and crypto markets news into your hands.

Add New Playlist